Highlights Addex Therapeutics Ltd Nasdaq

Equities

Market Closed - Nasdaq Other stock markets 04:30:00 2024-06-27 pm EDT			5-day change	1st Jan Change
8.165 ^USD	+2.32%		-1.51%	+34.96%

Jun. 06	Transcript : Addex Therapeutics Ltd, Q1 2024 Earnings Call, Jun 06, 2024
Jun. 06	Addex Therapeutics' Q1 Net Loss Widens; Revenue Down	MT

Addex Therapeutics' Q1 Net Loss Widens; Revenue Down	Jun. 06	MT
European Equities Traded in the US as American Depositary Receipts Decline	Apr. 30	MT
Sector Update: Health Care Stocks Edge Higher Late Afternoon	Apr. 29	MT
Sector Update: Health Care	Apr. 29	MT
Top Midday Decliners	Apr. 29	MT
Addex Therapeutics Shares Plunge as Phase 2 Study of ADX71149 Falls Short of Primary Goal	Apr. 29	MT
Tech Rally Subsides as US Equity Futures Waver Pre-Bell	Apr. 29	MT
Top Premarket Decliners	Apr. 29	MT
Addex Therapeutics Shares Plunge Premarket on Epilepsy Study Failure	Apr. 29	DJ
Addex Provides Update on ADX71149 Phase 2 Epilepsy Study	Apr. 29	CI
Addex Therapeutics Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 18	CI
Addex Therapeutics Logs Decline in FY23 Net Loss; Revenue Rises	Apr. 18	MT
Addex Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update	Apr. 18	DJ
ADRs End Higher; Biophytis Climbs 30%	Apr. 09	DJ
Wall Street Set to Open Slightly Higher as Investors Await Wednesday's Inflation Data	Apr. 09	MT
Top Premarket Gainers	Apr. 09	MT
ADRs Advance, Eco Wave Power Global AB Climbs 213.4%	Apr. 08	DJ
Top Premarket Gainers	Apr. 03	MT
Addex Therapeutics Announces the Launch of Neurosterix, Company Focused on Developing Allosteric Modulators for the Treatment of Underserved Neurological Disorders	Apr. 03	CI
Addex and Perceptive Launch Neurosterix with $63 Million to Accelerate Development of Allosteric Modulator Therapeutics for Neurological Disorders	Apr. 03	DJ

No results for this search